$INCY
INCYTE CORP Stock $incy

$incy Overview Financials Valuation SEC Filings Company Website

2013 Q4 Form 10-Q Financial Statement

#000110465913079662 Filed on October 31, 2013

Income Statement

Concept	2013 Q4	2013 Q3	2012 Q4
Revenue	$97.07M	$85.12M	$113.8M
YoY Change	-14.73%	40.72%	294.08%
Cost Of Revenue	$200.0K	$155.0K	$100.0K
YoY Change	100.0%	400.0%
Gross Profit	$96.90M	$84.97M	$113.7M
YoY Change	-14.78%	40.53%
Gross Profit Margin	99.82%	99.82%	99.87%
Selling, General & Admin	$38.00M	$26.45M	$23.70M
YoY Change	60.34%	28.88%	11.79%
% of Gross Profit	39.22%	31.13%	20.84%
Research & Development	$75.00M	$71.70M	$59.80M
YoY Change	25.42%	43.18%	15.22%
% of Gross Profit	77.4%	84.39%	52.59%
Depreciation & Amortization	$8.800M	$4.600M	$7.800M
YoY Change	12.82%	-39.47%	9.86%
% of Gross Profit	9.08%	5.41%	6.86%
Operating Expenses	$113.0M	$98.15M	$83.50M
YoY Change	35.33%	39.03%	14.38%
Operating Profit	-$16.10M	-$13.18M	$30.20M
YoY Change	-153.31%	30.04%
Interest Expense	-$8.400M	$7.699M	-$11.40M
YoY Change	-26.32%	-33.47%	4.59%
% of Operating Profit			-37.75%
Other Income/Expense, Net	-$200.0K	-$1.500M
YoY Change
Pretax Income	-$42.70M	-$21.99M	$18.90M
YoY Change	-325.93%	1.4%	-134.3%
Income Tax	$100.0K	$49.00K	$100.0K
% Of Pretax Income			0.53%
Net Earnings	-$42.90M	-$22.00M	$18.80M
YoY Change	-328.19%	1.38%	-134.12%
Net Earnings / Revenue	-44.19%	-25.84%	16.51%
Basic Earnings Per Share			$0.14
Diluted Earnings Per Share	-$265.0K	-$141.8K	$0.14
COMMON SHARES
Basic Shares Outstanding	161.1M shares	153.1M shares	131.7M shares
Diluted Shares Outstanding			139.1M shares

Balance Sheet

Concept	2013 Q4	2013 Q3	2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$509.0M	$291.2M	$228.4M
YoY Change	122.85%	19.54%	-17.72%
Cash & Equivalents	$471.4M	$272.1M	$224.1M
Short-Term Investments	$37.60M	$19.10M	$4.400M
Other Short-Term Assets	$11.00M	$9.000M	$9.900M
YoY Change	11.11%	-51.09%	-63.06%
Inventory	$406.0K	$359.0K	$278.0K
Prepaid Expenses
Receivables	$35.40M	$33.20M	$71.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$555.8M	$333.7M	$309.5M
YoY Change	79.57%	19.74%	-0.41%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.85M	$6.201M	$6.348M
YoY Change	322.94%	0.52%	-1.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$29.40M	$14.90M	$8.500M
YoY Change	245.88%	198.0%	142.86%
Total Long-Term Assets	$73.77M	$23.66M	$20.91M
YoY Change	252.88%	32.85%	14.96%
TOTAL ASSETS
Total Short-Term Assets	$555.8M	$333.7M	$309.5M
Total Long-Term Assets	$73.77M	$23.66M	$20.91M
Total Assets	$629.6M	$357.4M	$330.4M
YoY Change	90.54%	20.53%	0.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$19.10M	$18.21M	$13.96M
YoY Change	36.82%	42.68%	-6.55%
Accrued Expenses	$46.06M	$41.74M	$28.39M
YoY Change	62.28%	83.48%	14.61%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$108.0M	$109.5M	$136.1M
YoY Change	-20.6%	-20.45%	0.34%
LONG-TERM LIABILITIES
Long-Term Debt	$681.5M	$187.1M	$331.1M
YoY Change	105.83%	-42.4%	4.71%
Other Long-Term Liabilities	$26.80M	$3.392M	$38.20M
YoY Change	-29.84%	-93.73%	-63.37%
Total Long-Term Liabilities	$26.80M	$3.392M	$369.3M
YoY Change	-92.74%	-99.1%	-12.18%
TOTAL LIABILITIES
Total Short-Term Liabilities	$108.0M	$109.5M	$136.1M
Total Long-Term Liabilities	$26.80M	$3.392M	$369.3M
Total Liabilities	$822.7M	$328.6M	$505.4M
YoY Change	62.78%	-36.38%	-9.11%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.737B	-$1.694B	-$1.654B
YoY Change	5.03%	1.29%	2.75%
Common Stock	$1.542B	$1.721B	$1.477B
YoY Change	4.39%	18.64%	6.97%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$193.1M	$28.79M	-$175.0M
YoY Change
Total Liabilities & Shareholders Equity	$629.6M	$357.4M	$330.4M
YoY Change	90.54%	20.53%	0.44%

Cashflow Statement

Concept	2013 Q4	2013 Q3	2012 Q4
OPERATING ACTIVITIES
Net Income	-$42.90M	-$22.00M	$18.80M
YoY Change	-328.19%	1.38%	-134.12%
Depreciation, Depletion And Amortization	$8.800M	$4.600M	$7.800M
YoY Change	12.82%	-39.47%	9.86%
Cash From Operating Activities	-$11.70M	-$11.90M	-$22.00M
YoY Change	-46.82%	-56.09%	-44.72%
INVESTING ACTIVITIES
Capital Expenditures	-$2.100M	-$800.0K	-$900.0K
YoY Change	133.33%	100.0%	-10.0%
Acquisitions
YoY Change
Other Investing Activities	-$17.90M	-$200.0K	$500.0K
YoY Change	-3680.0%	-300.0%	-600.0%
Cash From Investing Activities	-$19.90M	-$1.000M	-$500.0K
YoY Change	3880.0%	233.33%	-54.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	230.9M	26.90M	7.500M
YoY Change	2978.67%	202.25%	316.67%
NET CHANGE
Cash From Operating Activities	-11.70M	-11.90M	-22.00M
Cash From Investing Activities	-19.90M	-1.000M	-500.0K
Cash From Financing Activities	230.9M	26.90M	7.500M
Net Change In Cash	199.3M	14.00M	-15.00M
YoY Change	-1428.67%	-175.68%	-61.64%
FREE CASH FLOW
Cash From Operating Activities	-$11.70M	-$11.90M	-$22.00M
Capital Expenditures	-$2.100M	-$800.0K	-$900.0K
Free Cash Flow	-$9.600M	-$11.10M	-$21.10M
YoY Change	-54.5%	-58.43%	-45.62%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2012Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	2483000	USD
CY2013Q3	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	2008000	USD
CY2012Q4	us-gaap	Availableforsale Securities Gross Unrealized Gain AvailableforsaleSecuritiesGrossUnrealizedGain	1878000	USD
CY2013Q3	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	19052000	USD
CY2012Q4	us-gaap	Available For Sale Securities Fair Value Disclosure AvailableForSaleSecuritiesFairValueDisclosure	4361000	USD
CY2012Q4	us-gaap	Inventory Noncurrent InventoryNoncurrent	8475000	USD
CY2013Q3	us-gaap	Inventory Noncurrent InventoryNoncurrent	14948000	USD
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2013Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	161119554	shares
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2013
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2012Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	591000	USD
CY2013Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	591000	USD
CY2012Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	7884000	USD
CY2013Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14357000	USD
CY2012Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	278000	USD
CY2013Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	359000	USD
CY2012Q4	incy	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	8753000	USD
CY2013Q3	incy	Inventory Net Current And Noncurrent InventoryNetCurrentAndNoncurrent	15307000	USD
CY2012Q4	us-gaap	Inventory Net InventoryNet	278000	USD
CY2013Q3	us-gaap	Inventory Net InventoryNet	359000	USD
CY2013Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28600000	USD
CY2012Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9500000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29400000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Method Used ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed	Black-Scholes valuation model
CY2013Q2	incy	Grant Receivable Related To Retention And Expansion Of Workforce Maximum GrantReceivableRelatedToRetentionAndExpansionOfWorkforceMaximum	11000000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	46024293	shares
	incy	Proceeds From Grant Related To Retention And Expansion Of Workforce ProceedsFromGrantRelatedToRetentionAndExpansionOfWorkforce	5000000	USD
CY2013Q2	incy	Facility Lease Term FacilityLeaseTerm	P15Y
CY2013Q2	incy	Square Footage Of Laboratory And Office On Lease SquareFootageOfLaboratoryAndOfficeOnLease	190000
CY2013Q2	us-gaap	Loss Contingency New Claims Filed Number LossContingencyNewClaimsFiledNumber	2	item
	dei	Entity Registrant Name EntityRegistrantName	INCYTE CORP
	dei	Entity Central Index Key EntityCentralIndexKey	0000879169
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2013-09-30
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	70236979	shares
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	224057000	USD
CY2012Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4361000	USD
CY2012Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	70951000	USD
CY2012Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9867000	USD
CY2012Q4	us-gaap	Assets Current AssetsCurrent	309514000	USD
CY2012Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6348000	USD
CY2012Q4	incy	Intangible And Other Assets Net IntangibleAndOtherAssetsNet	6082000	USD
CY2012Q4	us-gaap	Assets Assets	330419000	USD
CY2012Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	13961000	USD
CY2012Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	22899000	USD
CY2012Q4	us-gaap	Interest Payable Current InterestPayableCurrent	4750000	USD
CY2012Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	28385000	USD
CY2012Q4	incy	Deferred Collaborative Agreements Revenue Current DeferredCollaborativeAgreementsRevenueCurrent	66079000	USD
CY2012Q4	us-gaap	Liabilities Current LiabilitiesCurrent	136074000	USD
CY2012Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	322043000	USD
CY2012Q4	us-gaap	Convertible Subordinated Debt Noncurrent ConvertibleSubordinatedDebtNoncurrent	9033000	USD
CY2012Q4	incy	Deferred Collaborative Agreements Revenue Noncurrent DeferredCollaborativeAgreementsRevenueNoncurrent	38226000	USD
CY2012Q4	us-gaap	Liabilities Liabilities	505376000	USD
CY2012Q4	us-gaap	Common Stock Value CommonStockValue	133000	USD
CY2012Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1476922000	USD
CY2012Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	1878000	USD
CY2012Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1653890000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	-174957000	USD
CY2012Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	330419000	USD
CY2013Q3	us-gaap	Assets Current AssetsCurrent	333743000	USD
CY2013Q3	us-gaap	Assets Assets	357400000	USD
CY2013Q3	us-gaap	Liabilities Current LiabilitiesCurrent	109498000	USD
CY2013Q3	us-gaap	Liabilities Liabilities	328609000	USD
CY2013Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3392000	USD
CY2013Q3	us-gaap	Stockholders Equity StockholdersEquity	28791000	USD
CY2013Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	357400000	USD
CY2012Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	60000	USD
CY2012Q3	us-gaap	Investment Income Net InvestmentIncomeNet	27000	USD
CY2012Q3	us-gaap	Interest Expense InterestExpense	11573000	USD
CY2012Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21684000	USD
CY2012Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	26000	USD
CY2012Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21710000	USD
CY2012Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2012Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	130851	shares
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	58000	USD
CY2012Q3	us-gaap	Revenues Revenues	60492000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	92700000	USD
	us-gaap	Contracts Revenue ContractsRevenue	90211000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	302000	USD
	us-gaap	Revenues Revenues	183213000	USD
CY2012Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	31000	USD
CY2012Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50079000	USD
CY2012Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	20520000	USD
CY2012Q3	us-gaap	Costs And Expenses CostsAndExpenses	70630000	USD
CY2012Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10138000	USD
CY2012Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2012Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2012Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2012Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2012Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2013Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	400000000	shares
CY2012Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	133462185	shares
CY2013Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	160881043	shares
CY2012Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	133462185	shares
CY2013Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	160881043	shares
CY2012Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	43695000	USD
CY2012Q3	us-gaap	Contracts Revenue ContractsRevenue	16737000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	150627000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	61634000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	212319000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29106000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	393000	USD
	us-gaap	Interest Expense InterestExpense	34293000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-63006000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	93000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-63099000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.49
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	129093	shares
CY2013Q3	us-gaap	Revenues Revenues	85123000	USD
	us-gaap	Revenues Revenues	257875000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	98306000	USD
	us-gaap	Costs And Expenses CostsAndExpenses	257836000	USD
CY2013Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-13183000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	39000	USD
CY2013Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-21988000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-40114000	USD
CY2013Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-22037000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40276000	USD
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.28
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	155067	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	143899	shares
CY2013Q3	us-gaap	Royalty Revenue RoyaltyRevenue	8184000	USD
	us-gaap	Royalty Revenue RoyaltyRevenue	19893000	USD
CY2013Q3	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	1491000	USD
	us-gaap	Induced Conversion Of Convertible Debt Expense InducedConversionOfConvertibleDebtExpense	11262000	USD
CY2012Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	429000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	507000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	15000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	130000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	507000	USD
CY2013Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-22022000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40146000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-62592000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22214000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	140000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	29426000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10125000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8370000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1672000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-2175000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3220000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2332000	USD
	incy	Increase Decrease Deferred Revenue Collaborative Agreements IncreaseDecreaseDeferredRevenueCollaborativeAgreements	-50209000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1909000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-72822000	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	15024000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	20869000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	421000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1488000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-17463000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	40229000	USD
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	11262000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	40229000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	44659000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	48065000	USD
	us-gaap	Net Cash Provided By Used In Continuing Operations NetCashProvidedByUsedInContinuingOperations	-34081000	USD
CY2013Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	272122000	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	273164000	USD
CY2012Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	239083000	USD
	us-gaap	Interest Paid InterestPaid	9500000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	1000	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">1.</font></b><b><font style="FONT-SIZE: 3pt; FONT-WEIGHT: bold;" size="1">             </font></b> <b><font style="FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Organization and business</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">Incyte Corporation (“Incyte,” “we,” “us,” “our” or the “Company”) is a biopharmaceutical company focused on developing and commercializing proprietary small molecule drugs for oncology and inflammation. Our pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI</font><font style="POSITION: relative; FONT-SIZE: 6.5pt; TOP: -3pt;" size="1">®</font><font style="FONT-SIZE: 10pt;" size="2"> (ruxolitinib).</font></p> </div>
CY2013Q3	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2012Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	429000	USD
CY2012Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-21281000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	162000	USD
CY2013Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	15000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	130000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	20355000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	28577000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-37754000	USD
CY2013Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	19052000	USD
CY2013Q3	us-gaap	Accounts Receivable Net AccountsReceivableNet	33197000	USD
CY2013Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9013000	USD
CY2013Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6201000	USD
CY2013Q3	incy	Intangible And Other Assets Net IntangibleAndOtherAssetsNet	2508000	USD
CY2013Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	18212000	USD
CY2013Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	17957000	USD
CY2013Q3	us-gaap	Interest Payable Current InterestPayableCurrent	6087000	USD
CY2013Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	41739000	USD
CY2013Q3	incy	Deferred Collaborative Agreements Revenue Current DeferredCollaborativeAgreementsRevenueCurrent	25503000	USD
CY2013Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	187136000	USD
CY2013Q3	incy	Deferred Collaborative Agreements Revenue Noncurrent DeferredCollaborativeAgreementsRevenueNoncurrent	28583000	USD
CY2013Q3	us-gaap	Common Stock Value CommonStockValue	161000	USD
CY2013Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1720788000	USD
CY2013Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	2008000	USD
CY2013Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1694166000	USD
CY2013Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	60201000	USD
CY2013Q3	us-gaap	Contracts Revenue ContractsRevenue	16737000	USD
CY2013Q3	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	1000	USD
CY2013Q3	us-gaap	Cost Of Goods Sold CostOfGoodsSold	155000	USD
CY2013Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	71704000	USD
CY2013Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	26447000	USD
CY2013Q3	us-gaap	Investment Income Net InvestmentIncomeNet	385000	USD
CY2013Q3	us-gaap	Interest Expense InterestExpense	7699000	USD
CY2013Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	49000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	162589000	USD
	us-gaap	Contracts Revenue ContractsRevenue	75211000	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	182000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	463000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	185417000	USD
	us-gaap	Investment Income Net InvestmentIncomeNet	829000	USD
	us-gaap	Interest Expense InterestExpense	29720000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2644000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	6554000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	4251000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	13075000	USD
	incy	Increase Decrease Deferred Revenue Collaborative Agreements IncreaseDecreaseDeferredRevenueCollaborativeAgreements	-50219000	USD
	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	2236000	USD
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	-203000	USD
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	55921000	USD
	us-gaap	Interest Paid InterestPaid	9500000	USD
CY2013Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	80000000	USD
	incy	Improvements Cost Payable ImprovementsCostPayable	10000000	USD
	incy	Letter Of Credit For Issued For Lease Facility LetterOfCreditForIssuedForLeaseFacility	15000000	USD

Files In Submission

Name	View Source	Status
0001104659-13-079662-index-headers.html	Edgar Link	pending
0001104659-13-079662-index.html	Edgar Link	pending
0001104659-13-079662.txt	Edgar Link	pending
0001104659-13-079662-xbrl.zip	Edgar Link	pending
a13-19498_110q.htm	Edgar Link	pending
a13-19498_1ex10d1.htm	Edgar Link	pending
a13-19498_1ex31d1.htm	Edgar Link	pending
a13-19498_1ex31d2.htm	Edgar Link	pending
a13-19498_1ex32d1.htm	Edgar Link	pending
a13-19498_1ex32d2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
incy-20130930.xml	Edgar Link	completed
incy-20130930.xsd	Edgar Link	pending
incy-20130930_cal.xml	Edgar Link	unprocessable
incy-20130930_def.xml	Edgar Link	unprocessable
incy-20130930_lab.xml	Edgar Link	unprocessable
incy-20130930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$INCY
INCYTE CORP Stock $incy

2013 Q4 Form 10-Q Financial Statement

#000110465913079662 Filed on October 31, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INCY INCYTE CORP Stock $incy

2013 Q4 Form 10-Q Financial Statement

#000110465913079662 Filed on October 31, 2013

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$INCY
INCYTE CORP Stock $incy